SPRINGFIELD, Mass., Oct. 16, 2019 /PRNewswire/ -- Registered nurses from across the Commonwealth who are gathering for the annual convention of the Massachusetts Nurses Association will march from MGM Springfield to Monarch Place on Thursday, Oct. 17 to protest the widespread and devastating reductions to patient care services that Baystate

SAN MATEO, Calif., Oct. 16, 2019 /PRNewswire/ -- Human API - a real-time consumer health data platform - today announced that it has joined the Google Cloud Partner Advantage Program to further engage consumers to connect and share their health data, no matter where or how it was stored.

FORT WORTH, Texas, Oct. 16, 2019 /PRNewswire/ -- Eyevance Pharmaceuticals, committed to developing and commercializing innovative and impactful ophthalmic products, is pleased to announce the acquisition of TOBRADEX® ST (tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05% and NATACYN® (natamycin ophthalmic suspension) 5% from Novartis.

SAN FRANCISCO, Oct. 16, 2019 /PRNewswire/ -- Perricone MD is taking a monumental leap into the acne market with its new Acne Relief Prebiotic Acne Therapy, a 90-day system that selectively targets and treats the three main causes of acne: excess oil, acne-causing bacteria and inflammation, unlike other acne products that typically target one cause. Acne Relief

ALBANY, N.Y., Oct. 16, 2019 /PRNewswire/ -- Hixny and Price Chopper/Market 32 announced today that the progressive New York-based supermarket chain with 82 p

TEL AVIV, Israel and BETHESDA, Maryland, Oct. 16, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that the final results of its pilot

ALBANY, Ga., Oct. 16, 2019 /PRNewswire/ -- Peanuts have it all. They're tasty, low-cost and packed with protein, vitamins and minerals. To celebrate this superfood, The Peanut Institute

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced the pricing of an underwritten public offering of 40,000,000 units at a price to the public of $0.225 per unit. Each unit issued in the offering consists of one share of common stock (or pre-funded warrant in lieu thereof) an

The Chubb Cyber IndexSM provides global claims and policy data, incident response costs analysis, and insights into cyber insurance limits and deductibles WHITEHOUSE STATION, N.J., Oct. 16, 2019 /PRNewswire/ -- Chubb has enhanced its proprietary Chubb Cyber IndexSM with upgraded features that help identify a range of global cyber threats bas

SAN FRANCISCO, Oct. 16, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced the initiation of a first-in-human, Phase 1 clinical study evaluating NKTR-255, an interleukin-15 (IL-15) receptor agonist, as monotherapy for patients with relapsed or refractory non-Hodgkin lymphoma (NHL) or multiple myeloma (MM). The study will also combine NKTR-255 with mu